The Association for the Advancement of Medical Instrumentation (AAMI) has updated a standard with an additional measure that one expert says can help ensure that subpar healthcare gowns and drapes dont find their way into operating rooms.
The change to PB70 is going to tighten the standard up as to what is acceptable and can take to market, says Donna Swenson, cochair of AAMIs Protective Barrier Committee, which updated the document. Â
The standard includes the requirements for testing how well drapes and gowns used in surgeries protect the wearer from fluids. It classifies the products into four levels based on the amount of protection they offer. While the standard is primarily for manufacturers, healthcare providers also find it helpful, Swenson says.
The standard helps users understand when they pull a particular product off the shelf what kind of protection they can except to get from it, she says.
The change focuses on the acceptance criteria for a product lot. The standard adds what is called a rejectable quality level (RQL) to help determine if the test results are acceptable and if the product can be released, says Swenson.
The previous version of PB70 recommended manufacturers use only an acceptable quality level (AQL) to set the criteria. Now it recommends manufacturers use both AQL and RQL.
RQL is generally defined as that level of quality that the sampling plan will accept 10 percent of the time, Swenson says. This means lots at or worse than the RQL are acceptedat most10 percent of the time. In other words, they are rejected at least 90 percent of the time. Using both AQL and RQL criteria will provide a high probability that the consumer will only receive unacceptable product a very small percentage of the time.
The standard also includes a change that gives manufacturers greater latitude when testing their products, Swenson says. When manufacturers test their fabric, they place a blotter paper underneath it and then spray the fabric with water. The blotter paper absorbs whatever water goes through the fabric. The amount of water on the paper determines the products level of protection, Swenson says.
For years, manufacturers have used a test from the American Association of Textile Chemists and Colorists (AATCC), but the blotter paper employed in that test is no longer being manufactured, although some test houses still have a supply. The standard now allows manufacturers to use a test called WSP80.3, which does not require the use of any specific paper, but allows the use of any blotter paper that meets the specifications in PB70. It is a similar test that should give equivalent results, Swenson says. It is just giving manufacturers a little bit of flexibility, but maintaining the same standard.Â
The standards full title is ANSI/AAMI PB70:2012, Liquid barrier performance and classification of protective apparel and drapes intended for use in healthcare facilities.
The list price is $100, and the AAMI member price is $50. The order code is PB70 or PB70-PDF. To order copies, call (877) 249-8226, or shop the AAMI store at www.aami.org.
Source: Association for the Advancement of Medical Instrumentation (AAMI)Â
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.